Clicky

Race Oncology Ltd  (RAC)

Description: Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.


Keywords: Medicine Pharmaceutical Cancer Clinical Medicine Drugs Oncology Chemotherapy Acute Myeloid Leukemia Leukemia Isan Anthracycline Bisantrene

Home Page: www.raceoncology.com

RAC Technical Analysis

Gateway, 1 Macquarie Place
Sydney, NSW 2000
Australia
Phone: 61 2 8051 3043


Officers

Name Title
Mr. Phillip R. Lynch CEO, MD & Director
Dr. Daniel Tillett Chief Scientific Officer & Exec. Director
Ms. Christina Manfre Chief Financial Officer
Dr. Ajay Duggal Dip Pharm Med, MB ChB, MRCP Interim Chief Medical Officer
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec.

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 9.5982
Price-to-Sales TTM: 467.7607
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks